News Feed Item

New International Bureau for Epilepy Survey Highlights 'What Really Matters' to People With Epilepsy Today

ROME, August 29, 2011 /PRNewswire/ --

Weight gain revealed as most bothersome unwanted effect associated with epilepsy treatment

A new, on-going European survey to assess what really matters to people living with epilepsy today has been commissioned by the International Bureau for Epilepsy (IBE), an international umbrella organisation of national epilepsy patient groups. This survey marks the 50th anniversary of the IBE and this five decade landmark provides a timely opportunity to uncover the key issues faced by patients and carers in 2011 with the hope of improving standards of care in the future.

Presented today at the International Epilepsy Congress, the preliminary results of the survey, drawn from over 120 patients in 17 countries, show that weight gain is considered to be the most bothersome unwanted effect associated with epilepsy medication. Dizziness and slowing of mental agility were listed as being the next most disturbing unwanted effects. In general, survey respondents acknowledged that they experienced side effects with their current epilepsy treatment, although stated that they were not unduly bothered by this, and many stated that they simply forget to raise the issue of unwanted effects with their doctor or nurse. However, the majority of respondents stated that they 'sometimes' worry about the long term effects of their treatment.

Also revealed in the initial results were issues relating to concordance with treatment. The majority of respondents admitted that they forgot to take their epilepsy treatment as prescribed once a month and the majority of respondents felt that they found it 'not very easy' to remember to take their epilepsy treatment.

"We believe this type of people with epilepsy-centric insight is vital in helping us to improve epilepsy care in the future", points out IBE President Mike Glynn. "Enormous progress has been made over the past five decades in epilepsy care and treatment, but there is still a long way to go. Sadly, epilepsy still continues to take its toll, impairing the physical, psychological and social functioning of those affected and their families. We must listen to people with epilepsy and acknowledge what they really feel about their epilepsy and associated treatment approaches in order improve their daily lives."

The survey uses a web-based questionnaire that has been translated into 12 languages. The easy-to-complete questionnaire is distributed through the IBE's country chapters via e-mail and probes into patients' personal experiences of the impact of epilepsy, their epilepsy management and the aspects of epilepsy and its care that matter most to them.

The survey was funded through an unrestricted educational grant provided by Eisai. The field work commenced in July 2011 and will end mid-September this year. Full survey results will be available before the end of 2011.

*** ENDS ***

Notes to Editors

About the IBE

The International Bureau for Epilepsy (IBE) is a worldwide umbrella organisation, with a powerful global network of 122 members in 92 countries, providing a platform for the representation of epilepsy and promoting understanding and knowledge of the condition. IBE Members are lay organizations, with membership accessible to all.

Members are grouped regionally, in line with the regional boundaries adopted by the WHO, so that every member of IBE is also a member of a Regional Committee.

50 years focused on epilepsy

Created in 1961, this year marks the 50th anniversary of the IBE and the Golden Jubilee of its foundation. Throughout the past five decades, the IBE has focused on improving epilepsy care and remains committed to finding new and innovative solutions to the problems impacting people with epilepsy and their families world-wide.

For further information please visit the IBE's web site http://www.ibe-epilepsy.org

Eisai in epilepsy

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of anti-epileptic drugs (AEDs) is a major strategic area for Eisai.

About Eisai

Eisai is one of the world's leading R&D-based pharmaceutical companies and has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas: neuroscience; oncology and vascular / immunological reaction.

With operations in the U.S., Asia, Europe and its domestic home market of Japan, we employ more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary, Slovakia and the Netherlands.

For further information please visit Eisai's web site http://www.eisai.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
@DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises - and delivering real results.
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...